BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37990130)

  • 1. EZH2 is a key component of hepatoblastoma tumor cell growth.
    Glaser K; Schepers EJ; Zwolshen HM; Lake CM; Timchenko NA; Karns RA; Cairo S; Geller JI; Tiao GM; Bondoc AJ
    Pediatr Blood Cancer; 2024 Feb; 71(2):e30774. PubMed ID: 37990130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader.
    Yu X; Wang J; Gong W; Ma A; Shen Y; Zhang C; Liu X; Cai L; Liu J; Wang GG; Jin J
    Oncogene; 2023 Mar; 42(13):994-1009. PubMed ID: 36747009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
    Chen Q; Zheng PS; Yang WT
    Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitous expressed transcript promotes tumorigenesis by acting as a positive modulator of the polycomb repressive complex 2 in clear cell renal cell carcinoma.
    Zeng J; Xiang W; Zhang Y; Huang C; Chen K; Chen Z
    BMC Cancer; 2019 Sep; 19(1):874. PubMed ID: 31481081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The noncanonical role of EZH2 in cancer.
    Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
    Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone H3K27 methylation mark regulates intestinal epithelial cell density-dependent proliferation and the inflammatory response.
    Turgeon N; Blais M; Delabre JF; Asselin C
    J Cell Biochem; 2013 May; 114(5):1203-15. PubMed ID: 23192652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
    Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer.
    Chen J; Hong JH; Huang Y; Liu S; Yin J; Deng P; Sun Y; Yu Z; Zeng X; Xiao R; Chan JY; Guan P; Wang Y; Wang P; Liu L; Wen S; Yu Q; Ong CK; Teh BT; Xiong Y; Tan J
    Mol Cancer; 2023 May; 22(1):85. PubMed ID: 37210576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
    Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
    Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
    Li Y; Ren Y; Wang Y; Tan Y; Wang Q; Cai J; Zhou J; Yang C; Zhao K; Yi K; Jin W; Wang L; Liu M; Yang J; Li M; Kang C
    Theranostics; 2019; 9(16):4608-4623. PubMed ID: 31367244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of bacterial infection in the epigenetic regulation of Wnt antagonist WIF1 by PRC2 protein EZH2.
    Roy BC; Subramaniam D; Ahmed I; Jala VR; Hester CM; Greiner KA; Haribabu B; Anant S; Umar S
    Oncogene; 2015 Aug; 34(34):4519-30. PubMed ID: 25486432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-214 targets β-catenin pathway to suppress invasion, stem-like traits and recurrence of human hepatocellular carcinoma.
    Xia H; Ooi LL; Hui KM
    PLoS One; 2012; 7(9):e44206. PubMed ID: 22962603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
    Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
    J Virol; 2019 May; 93(9):. PubMed ID: 30814291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
    Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
    Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRC2 Is Dispensable
    Ferguson J; Devarajan M; DiNuoscio G; Saiakhova A; Liu CF; Lefebvre V; Scacheri PC; Atit RP
    G3 (Bethesda); 2018 Feb; 8(2):491-503. PubMed ID: 29223978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.